drugset / Trial / NCT06604949

A Study of Single Dose of LP-003 in Healthy Adult Subjects

NCT06604949

Phase 1 Active not recruiting 12 enrolled Longbio Pharma
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy subjects.

Timeline

Start
2024-10-23
Primary completion
2026-11
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LP-003 Unknown 200 mg Subcutaneous